Description
Structure & Identity
This is a two-peptide blend. CJC-1295 (no DAC), also called Modified GRF (1-29), is a 29-residue stabilized GHRH fragment. Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (CAS 170851-70-4). Each keeps its own structure and receptor target; the blend simply brings both into one preparation.
Research Background
The blend combines two complementary growth-hormone-axis mechanisms.
- GHRH arm. CJC-1295 acts at the GHRH receptor and has been studied for prolonged GH/IGF-1 stimulation [PMID: 16352683].
- Ghrelin arm. Ipamorelin is a selective secretagogue at the GHS-R1a receptor [PMID: 9849822].
- Axis activation. CJC-1295 activates the GH/IGF-1 axis in research models [PMID: 19386527].
- Skeletal Endpoints. Ipamorelin has been examined in skeletal endpoints in rodent GH-axis models [PMID: 10373343].
- Combined rationale. Engaging both receptors lets researchers approach the GH pathway from two angles.
These are research contexts, not approved uses, and the blend is intended for laboratory study.
Specifications
| Attribute | Value |
| Product type | Blend (two peptides, combined) |
| Component 1 | CJC-1295 (no DAC / Mod GRF 1-29), 5 mg |
| Component 2 | Ipamorelin, 5 mg (CAS 170851-70-4) |
| Total quantity | 10 mg per vial (5 mg + 5 mg) |
| Purity | ≥99% by reverse-phase HPLC (each component) |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Appearance | White to off-white solid |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water |
| Classification | Research use only |
Storage & Handling
Keep the sealed vial frozen at -20°C and shielded from light until use. After preparation, store the solution at 2-8°C and use it in your research within about two weeks. Warm the vial to room temperature before opening, and avoid repeated freeze-thaw cycles so both peptides stay intact.
Quality Assurance
The components of this blend are produced under research-grade manufacturing controls and verified by an independent lab before release. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with testing carried out by third-party laboratories, including Janoshik Analytical and domestic US labs. A certificate of analysis accompanies each batch, so the results trace to your material.
Frequently Asked Questions
What is the CJC-1295 / Ipamorelin blend?
It is a combination research product with 5 mg each of CJC-1295 (no DAC) and ipamorelin, pre-combined in one vial. It is studied in growth-hormone-axis research and supplied for research use only.
Why are these two peptides combined?
They act through different receptors, CJC-1295 at the GHRH receptor and ipamorelin at the ghrelin/GHS-R1a receptor, so pairing them lets researchers study the growth-hormone pathway from two complementary angles.
Which CJC-1295 is in the blend, DAC or no DAC?
The no-DAC form, also called Modified GRF (1-29). It has a shorter action than the DAC version, which is absent here.
Are the peptides chemically joined?
No, they are two separate molecules combined in one vial, each keeping its own structure and receptor target.
How much of each peptide is in the vial?
There is 5 mg of CJC-1295 (no DAC) and 5 mg of ipamorelin, for 10 mg total.
Is the CJC-1295 + Ipamorelin blend FDA approved?
No, neither component nor the blend is FDA approved. The material here is a research-use-only preparation, not for human or veterinary use.
How should the blend be stored?
Keep the powder frozen at -20°C and protected from light. Once reconstituted for research, store at 2-8°C and use within about two weeks.
How are both components verified?
Each compound in the CJC-1295 + Ipamorelin blend is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch ships with a certificate of analysis.
